Clearside Biomedical to Participate in Two Upcoming Investor Conferences in June 2021
09 juin 2021 07h05 HE
|
Clearside Biomedical, Inc.
ALPHARETTA, Ga., June 09, 2021 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve...
Clearside Biomedical Announces First Quarter 2021 Financial Results and Provides Corporate Update
17 mai 2021 16h05 HE
|
Clearside Biomedical, Inc.
- Recent New Drug Application Resubmission for XIPERETM (triamcinolone acetonide suprachoroidal injectable suspension) - - Cohort 1 Data in OASIS Wet AMD Phase 1/2a Trial Expected in...
Clearside Biomedical Announces Multiple Poster Presentations at the Association for Research in Vision and Ophthalmology 2021 Virtual Meeting
10 mai 2021 07h05 HE
|
Clearside Biomedical, Inc.
ALPHARETTA, Ga., May 10, 2021 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve...
Clearside Biomedical to Report First Quarter 2021 Financial Results and Provide Corporate Update on Monday, May 17, 2021
04 mai 2021 07h05 HE
|
Clearside Biomedical, Inc.
ALPHARETTA, Ga., May 04, 2021 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve...
Clearside Biomedical Announces Resubmission of New Drug Application for XIPERE™ for Treatment of Macular Edema Associated with Uveitis
03 mai 2021 07h05 HE
|
Clearside Biomedical, Inc.
ALPHARETTA, Ga., May 03, 2021 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve...
Clearside Biomedical to Present at the Needham Virtual Healthcare Conference and Wet AMD & DME Drug Development Summit
05 avr. 2021 07h05 HE
|
Clearside Biomedical, Inc.
ALPHARETTA, Ga., April 05, 2021 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve...
Clearside Biomedical Announces Fourth Quarter and Full Year 2020 Financial Results and Provides Corporate Update
10 mars 2021 16h05 HE
|
Clearside Biomedical, Inc.
- OASIS Wet AMD Phase 1/2a Trial Initiated and Cohort 1 Dosing Completed - - Initial Safety Data from OASIS Trial Expected Mid-2021 - - Four Ongoing Internal & Partner Clinical Trials Using...
Clearside Biomedical Announces Completion of Patient Dosing in First Cohort of Phase 1/2a Clinical Trial of CLS-AX (axitinib injectable suspension) for the Treatment of Wet AMD
02 mars 2021 07h05 HE
|
Clearside Biomedical, Inc.
- Initial Safety Data from First Cohort Expected Mid-2021 - ALPHARETTA, Ga., March 02, 2021 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to...
Clearside Biomedical to Report Fourth Quarter and Full Year 2020 Financial Results and Provide Corporate Update on Wednesday, March 10, 2021
24 févr. 2021 07h05 HE
|
Clearside Biomedical, Inc.
ALPHARETTA, Ga., Feb. 24, 2021 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve...
Clearside Biomedical to Participate in Two Upcoming Investor Conferences in March 2021
23 févr. 2021 07h05 HE
|
Clearside Biomedical, Inc.
ALPHARETTA, Ga., Feb. 23, 2021 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve...